Precigen 超出了盈利预期，内部人士购买了股票，分析师将其评为“适度买入”，尽管季度亏损且市盈率为负。 Precigen beat earnings estimates, insiders bought shares, and analysts rate it a "Moderate Buy" despite a quarterly loss and negative P/E.

Precigen, Inc.(PGEN)有5名分析师的“机动购买”共识评级,12个月的平均价格目标是8.25美元。 Precigen, Inc. (PGEN) has a "Moderate Buy" consensus rating from five analysts, with a 12-month average price target of $8.25. 该公司的重点是免疫肿瘤、天免疫机能紊乱和传染病的基因和细胞疗法,报告每季度每股损失0.11美元,击打估计数3美元,收入86万美元,超过预测。 The company, focused on gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, reported a quarterly loss of $0.11 per share, beating estimates by $0.03, and generated $0.86 million in revenue, exceeding forecasts. 过去90天,内部人收购了41 005份股票,价值167 651美元,其中47.10%的股份由内部人持有。 Insiders acquired 41,005 shares valued at $167,651 over the past 90 days, with 47.10% of shares held by insiders. Nancy H. Agee董事通过以4.60美元购买15 000份股份增加了她的股份,而Randal J. Kirk董事则以3.68美元出售360万美元股份。 Director Nancy H. Agee increased her stake by purchasing 15,000 shares at $4.60, while Director Randal J. Kirk sold 3.6 million shares at $3.68. 股票以3.75美元关闭,市场上限为11.2亿美元,贝塔为1.82美元,P/E比率为负-8.93。 The stock closed at $3.75, with a market cap of $1.12 billion, a beta of 1.82, and a negative P/E ratio of -8.93. 分析员预测全年损失每股0.32美元。 Analysts project a full-year loss of $0.32 per share.